442 related articles for article (PubMed ID: 22466465)
1. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
3. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
4. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
Good TJ; Kimura AE; Mandava N; Kahook MY
Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
[TBL] [Abstract][Full Text] [Related]
6. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
7. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
8. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J
Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396
[TBL] [Abstract][Full Text] [Related]
9. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
[TBL] [Abstract][Full Text] [Related]
10. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
11. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
[TBL] [Abstract][Full Text] [Related]
12. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K
Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
[TBL] [Abstract][Full Text] [Related]
14. SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS: What Is the Evidence?
Dedania VS; Bakri SJ
Retina; 2015 May; 35(5):841-58. PubMed ID: 25905784
[TBL] [Abstract][Full Text] [Related]
15. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
17. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
19. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund KB; Hoang QV; Saroj N; Thompson D
Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration.
Hosseini H; Lotfi M; Esfahani MH; Nassiri N; Khalili MR; Razeghinejad MR; Nouri-Mahdavi K
Retina; 2012 May; 32(5):967-71. PubMed ID: 22146127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
